Allogene Therapeutics, Inc. Other Long-term Investments
Allogene Therapeutics, Inc. (ALLO) had Other Long-term Investments of $352.18 million as of 2021-12-31, per its 10-K filed 2022-02-23.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments
us-gaap:OtherLongTermInvestments · last filed 2022-02-23
- 2021-12-31: Other Long-term Investments $352.18M.
- 2020-12-31: Other Long-term Investments $204.21M.
- 2019-12-31: Other Long-term Investments $58.32M.
- 2018-12-31: Other Long-term Investments $261.97M.
| Period end | Other Long-term Investments |
|---|---|
| 2021-12-31 | $352.18M 10-K · filed 2022-02-23 |
| 2020-12-31 | $204.21M 10-K · filed 2022-02-23 |
| 2019-12-31 | $58.32M 10-K · filed 2021-02-25 |
| 2018-12-31 | $261.97M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |